Gastric cancer: Classification, histology and application of molecular pathology.
暂无分享,去创建一个
A. Meloni-Ehrig | Aurelia Meloni-Ehrig | Bing Hu | Nassim El Hajj | Scott Sittler | Nancy Lammert | Robert Barnes | N. Lammert | R. Barnes | S. Sittler | Bing-qiang Hu | N. El Hajj
[1] B. Fridley,et al. Genetic regulation of &bgr;-ureidopropionase and its possible implication in altered uracil catabolism , 2008, Pharmacogenetics and genomics.
[2] M. Kraus,et al. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. , 1989, Genomics.
[3] M. Vijver,et al. HER2 testing in gastric cancer: a practical approach , 2012, Modern Pathology.
[4] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[5] B. Fridley,et al. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism , 2007, Pharmacogenetics and genomics.
[6] J. Yokota,et al. AMPLIFICATION OF c-erbB-2 ONCOGENE IN HUMAN ADENOCARCINOMAS IN VIVO , 1986, The Lancet.
[7] T. Yamamoto,et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.
[8] P. Chandrasoma,et al. Histology of the gastroesophageal junction: an autopsy study. , 2000, The American journal of surgical pathology.
[9] M. Pomper,et al. Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors , 2008, Nature Medicine.
[10] K. Maruyama,et al. Characteristics of gastric cancer invading to the proper muscle layer--with special reference to mortality and cause of death. , 1985, Japanese journal of clinical oncology.
[11] W J Macdonald,et al. GASTRIC CARCINOMA. , 1912, Canadian Medical Association journal.
[12] H. P. Wang,et al. Lymphoepithelioma-like carcinoma of the stomach: a subset of gastric carcinoma with distinct clinicopathological features and high prevalence of Epstein-Barr virus infection. , 1999, Hepato-gastroenterology.
[13] Time Trend Analysis of Gastric Cancer Incidence in Japan by Histological Types,1975-1989 , 2001 .
[14] A. Jimeno,et al. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] Kangsheng Wang,et al. Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression. , 2007, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[16] S N Thibodeau,et al. Origin of microsatellite instability in gastric cancer. , 1999, The American journal of pathology.
[17] R. Fodde,et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. , 1996, Gastroenterology.
[18] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[19] J. Pignon,et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Ursula Amstutz,et al. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. , 2011, Pharmacogenomics.
[21] L. Aaltonen,et al. Screening E‐cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred , 2002, Human mutation.
[22] Charles J. Lightdale,et al. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. , 2003, Gastrointestinal endoscopy.
[23] J. Fraumeni,et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. , 1991, JAMA.
[24] R. Seruca,et al. Role of pathology in the identification of hereditary diffuse gastric cancer: report of a Portuguese family , 2005, Virchows Archiv.
[25] H. Nakayama,et al. Molecular Pathobiology of Gastric Cancer , 2006, Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society.
[26] V. Pankratz,et al. Lymphocyte-Rich Gastric Cancer: Associations with Epstein-Barr Virus, Microsatellite Instability, Histology, and Survival , 2003, Modern Pathology.
[27] C. Chi,et al. A genome‐wide study of microsatellite instability in advanced gastric carcinoma , 2001, Cancer.
[28] C. V. D. van de Velde,et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.
[29] H. P. Wang,et al. Epstein-Barr virus-associated gastric carcinomas: relation to H. pylori infection and genetic alterations. , 2000, Gastroenterology.
[30] R. Seruca,et al. The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes. , 1998, The American journal of pathology.
[31] R. Genta,et al. Tumors of the Digestive System , 2013 .
[32] T. Yoshimura,et al. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975-1989 , 2001, British Journal of Cancer.
[33] E. Van Cutsem,et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] R. M. Huberman,et al. The gastric cardia in Helicobacter pylori infection. , 1994, Human pathology.
[35] P. Laurén,et al. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.
[36] D. Evans,et al. An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. , 1995, Journal of medical genetics.
[37] A. Akagi,et al. Role of Copper Accumulation in Spontaneous Renal Carcinogenesis in Long‐Evans Cinnamon Rats , 1999, Japanese journal of cancer research : Gann.
[38] R. Chetty,et al. Gastric pseudo-signet ring cells: a potential diagnostic pitfall , 2011, Virchows Archiv.
[39] J. Yokota,et al. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. , 2009, Gastroenterology.
[40] A. Meindl,et al. Strong Association of a Common Dihydropyrimidine Dehydrogenase Gene Polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients , 2008, PloS one.
[41] J. Isola,et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] K. Coombes,et al. Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology , 2009, 1010.1092.
[43] J. Parsonnet,et al. Helicobacter pylori infection in intestinal- and diffuse-type gastric adenocarcinomas. , 1991, Journal of the National Cancer Institute.
[44] E. Van Cutsem,et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] C Caldas,et al. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. , 2001, Gastroenterology.
[46] J. V. van Sandick,et al. Prognostic Value of Laurén Classification and c-erbB-2 Oncogene Overexpression in Adenocarcinoma of the Esophagus and Gastroesophageal Junction , 1999, Annals of Surgical Oncology.
[47] H. Mashimo,et al. Gastric cardiac carcinomas involving the esophagus are more adequately staged as gastric cancers by the 7th edition of the American Joint Commission on Cancer Staging System , 2011, Modern Pathology.
[48] Martin R. Johnson,et al. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[49] Amitabh Srivastava,et al. Micropapillary Carcinoma of Stomach: A Clinicopathologic and Immunohistochemical Study of 11 Cases , 2010, The American journal of surgical pathology.
[50] N. Nomura,et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor , 1986, Nature.
[51] S. Thibodeau,et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. , 1996, Cancer research.
[52] U. Hofmann,et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] S. Chin,et al. Germline CDH1 deletions in hereditary diffuse gastric cancer families , 2009, Human molecular genetics.
[54] G. Sauter,et al. HER-2 amplification is highly homogenous in gastric cancer. , 2010, Human pathology.
[55] Y. Seto,et al. Gastric carcinoma with invasive micropapillary pattern and its association with lymph node metastasis , 2011, Histopathology.
[56] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[57] Yoko Ito,et al. Mechanisms and sequelae of E‐cadherin silencing in hereditary diffuse gastric cancer , 2008, The Journal of pathology.
[58] Martin R. Johnson,et al. Rapid Identification of Dihydropyrimidine Dehydrogenase Deficiency by Using a Novel 2-13C-Uracil Breath Test , 2004, Clinical Cancer Research.
[59] J. Fraumeni,et al. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States , 1998, Cancer.
[60] J. Cooper. Ajcc Cancer Staging Manual , 1997 .
[61] A. V. van Kuilenburg,et al. Detection of β-ureidopropionase deficiency with HPLC–electrospray tandem mass spectrometry and confirmation of the defect at the enzyme level , 2001, Journal of Inherited Metabolic Disease.
[62] C. Punt,et al. Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer , 2011, Clinical Cancer Research.
[63] A. Valachis,et al. Translational Medicine and Reliability of Single-Nucleotide Polymorphism Studies: Can We Believe in SNP Reports or Not? , 2011, International journal of medical sciences.
[64] R. Diasio,et al. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy. , 2004, Clinical advances in hematology & oncology : H&O.
[65] J. Yokota,et al. Familial gastric cancer: overview and guidelines for management* , 1999, Journal of medical genetics.
[66] Joon-Oh Park,et al. Genetic Polymorphisms Associated with 5-Fluorouracil-Induced Neurotoxicity , 2010, Chemotherapy.
[67] D. Parkin. International variation , 2004, Oncogene.
[68] P. Miron,et al. Germline E-cadherin mutations in familial lobular breast cancer , 2007, Journal of Medical Genetics.
[69] A. Axon,et al. Early gastric cancer in Europe , 1997, Gut.
[70] D. Huntsman,et al. Genetic Screening for Familial Gastric Cancer , 2004, Hereditary cancer in clinical practice.
[71] H. Höfler,et al. Microsatellite instability and loss of heterozygosity in gastric carcinoma in comparison to family history. , 1998, The American journal of pathology.
[72] Takuma Sasaki,et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. , 1991, Cancer research.
[73] R. Diasio,et al. Predicting fluorouracil toxicity: can we finally do it? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] Martin R. Johnson,et al. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. , 2001, Advances in enzyme regulation.
[75] James C Yao,et al. Characteristics of Epstein-Barr virus-associated gastric cancer: A study of 235 cases at a comprehensive cancer center in U.S.A , 2009, Journal of experimental & clinical cancer research : CR.
[76] K. Cheng,et al. Classification of adenocarcinoma of the oesophagogastric junction , 1999, The British journal of surgery.
[77] H. Jung,et al. Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector‐row computed tomography , 2010, Journal of gastroenterology and hepatology.